271 related articles for article (PubMed ID: 28445097)
1. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.
Katakami N; Oda K; Tauchi K; Nakata K; Shinozaki K; Yokota T; Suzuki Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Jun; 35(17):1921-1928. PubMed ID: 28445097
[TBL] [Abstract][Full Text] [Related]
2. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis.
Esmadi M; Ahmad D; Hewlett A
J Gastrointestin Liver Dis; 2019 Mar; 28(1):41-46. PubMed ID: 30851171
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Dec; 35(34):3859-3866. PubMed ID: 28968171
[TBL] [Abstract][Full Text] [Related]
5. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
Webster LR; Yamada T; Arjona Ferreira JC
Pain Med; 2017 Dec; 18(12):2350-2360. PubMed ID: 28371937
[TBL] [Abstract][Full Text] [Related]
6. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study.
Webster LR; Nalamachu S; Morlion B; Reddy J; Baba Y; Yamada T; Arjona Ferreira JC
Pain; 2018 May; 159(5):987-994. PubMed ID: 29419653
[TBL] [Abstract][Full Text] [Related]
7. Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials.
Wild J; Yamada T; Arjona Ferreira JC; Hale M
Pain; 2019 Oct; 160(10):2358-2364. PubMed ID: 31145214
[TBL] [Abstract][Full Text] [Related]
8. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006332. PubMed ID: 29869799
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Naldemedine Administration for Opioid-Induced Constipation in Cancer Patients with Poor Performance Status.
Fujita Y; Imai H; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
J Palliat Med; 2023 Apr; 26(4):548-553. PubMed ID: 36971576
[No Abstract] [Full Text] [Related]
10. Naldemedine versus placebo in opioid-induced constipation: a meta-analysis.
Wobbe B; Gerner M; Köhne CH
BMJ Support Palliat Care; 2024 Jan; 13(e3):e578-e584. PubMed ID: 36517204
[TBL] [Abstract][Full Text] [Related]
11. Naldemedine: A Review in Opioid-Induced Constipation.
Blair HA
Drugs; 2019 Jul; 79(11):1241-1247. PubMed ID: 31267482
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
Wild J; Webster L; Yamada T; Hale M
Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
[TBL] [Abstract][Full Text] [Related]
13. Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study.
Takagi Y; Osawa G; Kato Y; Ikezawa E; Kobayashi C; Aruga E
BMC Gastroenterol; 2020 Jan; 20(1):25. PubMed ID: 32005157
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
Song X; Wang D; Qu X; Dong N; Teng S
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):121-128. PubMed ID: 30652502
[TBL] [Abstract][Full Text] [Related]
15. Naldemedine effective in treating opioid-induced constipation.
Brower V
Lancet Oncol; 2017 Jun; 18(6):e306. PubMed ID: 28483411
[No Abstract] [Full Text] [Related]
16. Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis.
Kistemaker KRJ; Sijani F; Brinkman DJ; de Graeff A; Burchell GL; Steegers MAH; van Zuylen L
Cancer Treat Rev; 2024 Apr; 125():102704. PubMed ID: 38452708
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer.
Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
Ann Oncol; 2018 Jun; 29(6):1461-1467. PubMed ID: 32151367
[TBL] [Abstract][Full Text] [Related]
18. Naldemedine (Symproic) for opioid-induced constipation.
Med Lett Drugs Ther; 2017 Dec; 59(1535):196-198. PubMed ID: 29186083
[No Abstract] [Full Text] [Related]
19. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain.
Webster L; Jansen JP; Peppin J; Lasko B; Irving G; Morlion B; Snidow J; Pierce A; Mortensen E; Kleoudis C; Carter E
Pain; 2008 Jul; 137(2):428-440. PubMed ID: 18164818
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of naldemedine treatment for opioid-induced constipation in gastrointestinal cancer: a retrospective analysis.
Nishiba H; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Mogi J; Obayashi K; Minato K
Ann Palliat Med; 2023 Jul; 12(4):697-707. PubMed ID: 37081703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
